Clin Osteol 2020; 25(1): 50-57

Atypical cases of secondary hyperparathyroidism in patients with kidney disease and failure: case reportsCase reports

Pokorná Anita1, Horáček Jiří2, Vávrová Jaroslava3, Chrobok Viktor4, Čelakovský Petr4, Šafránek Roman1,5, Ryba Miroslav6, Řehořková Pavla7, Pavlíková Ladislava3, Palička Vladimír3, Sulková Dusilová Sylvie1,5
1 Hemodialyzační středisko FN Hradec Králové
2 IV. interní hematologická klinika LF UK a FN Hradec Králové
3 Osteocentrum, Ústav klinické biochemie a diagnostiky LF UK a FN Hradec Králové
4 Klinika otorinolaryngologie a chirurgie hlavy a krku LF UK a FN Hradec Králové
5 Katedra interních oborů LF UK v Hradci Králové
6 Oddělení nefrologie a dialýzy, Krajská nemocnice Liberec, a. s.
7 Endokrinologie MUDr. Řehořková s. r. o., Hradecká poliklinika III s. r. o., Hradec Králové

The text is focused on clinical and laboratory manifestations of secondary hyperparathyroidism, associated with chronic kidney disease and chronic renal failure. Presenting four our case reports, we demonstrate not only the complex and complicated "traditional" SHPT pathogenesis associated with kidney disease, but also others involving and contributing factors and problems. First, in some patients, it may be difficult to properly recognize between primary and secondary hyperparathyroidism. Additionally, the role of vitamin D deficiency as the crucial factor in parathyroid gland stimulation is demonstrated. Also, the role of dialysis solution composition on parathyroid gland activity is described. All case reports are presented together with commentaries, which contain the pathophysiological explanation as well as the suggested therapeutic approach.

Keywords: vitamin D; hyperparathyreosis; hyperplasia; parathyroidectomy; parathyroid adenoma; parathyroid gland; secondary kidney disease; kidney failure

Received: October 28, 2019; Accepted: December 9, 2019; Published: June 11, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pokorná A, Horáček J, Vávrová J, Chrobok V, Čelakovský P, Šafránek R, et al.. Atypical cases of secondary hyperparathyroidism in patients with kidney disease and failure: case reports. Clinical Osteology. 2020;25(1):50-57.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011; 6(4): 913-921. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.06040710>. Go to original source...
    2. Moe S, Drüeke T, Cunningham J et al. CKD-MBD: Definition, Evaluation, and Classification of Renal Osteodystrophy: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69(11): 1945-1953. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.ki.5000414>. Go to original source...
    3. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease -⁠ mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011); 7(1): 1-59. Dostupné z DOI: <http://dx.doi.org/10.1016/j.kisu.2017.04.001>. Go to original source...
    4. Fraser WD. Hyperparathyroidism. Lancet 2009; 374(9684): 145-168. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(09)60507-9>. Go to original source...
    5. R Nuti, Merlotti D, Gennari Let al. Vitamin D Deficiency and Primary Hyperparathyroidism. J Endocrinol Invest 2001; 34(7 Suppl): 45-49.
    6. Messa P, Alfiery CM. Secondary and tertiary hyperparathyroidism. Front Horm Res 2019; 51 : 91-108. Dostupné z DOI: <http://dx.doi.org/10.1159/000491041>. Go to original source...
    7. Jamal SA, Miller PD. Secondary and tertiary hyperparathyroidism. J Clin Densitom 2013; 16(1): 64-68. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jocd.2012.11.012>. Go to original source...
    8. Duan K, Gomez-Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol 2015; 68(10): 771-787. Dostupné z DOI: <http://dx.doi.org/10.1136/jclinpath-2015-203186>. Go to original source...
    9. Goviale MC, Bellavia M, Damiano G et al. Post-transplantation tertiary hyperparathyroidism. Ann Transplant 2012; 17(3): 111-119. Go to original source...
    10. Phelps KR. Trade-off-the Nephron: A theory to explain the primacy of phosphate in the pathogenesis of secondary hyperparathyroidism. Nutrients 2017 : 9(5): 427. Dostupné z DOI: <http://dx.doi.org/10.3390:nu9050427>. Go to original source...
    11. Lowe H, McMahon DJ, Rubin MR et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrin Metab 2007; 92(8): 3001-3005. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2006-2802>. Go to original source...
    12. Centeno PP, Hergerger A, Mun HC et al. Phosphate Acts Directly on the Calcium-Sensing Receptor to Stimulate Parathyroid Hormone Secretion. Nat Commun 2019; 10(1): 4693. Dostupné z DOI: <http://dx.doi.org/10.1038/s41467-019-12399-9>. Go to original source...
    13. Phelps KR. Trade-off-the Nephron: A theory to explain the primacy of phosphate in the pathogenesis of secondary hyperparathyroidism. Nutrients 2017; 9(5): 427. Dostupné z DOI: <http://dx.doi.org/10.3390:nu9050427>. Go to original source...
    14. Blaine J, Weinman EJ, Cunningham R et al. The Regulation of Renal Phosphate Transport. Adv Chronic Kidney Dis 2011; 18(2): 77-84. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ackd.2011.01.005>. Go to original source...
    15. Levi M, Gratton E, Forster IC et al. Mechanisms of Phosphate Transport. Nat Rev Nephrol 2019; 15(8): 482-500. Dostupné z DOI: <http://dx.doi.org/10.1038/s41581-019-0159-y>. Go to original source...
    16. Rodriguez M, Lorenzo V. Parathyroid Hormone, a Uremic Toxin. Semin Dial 2009; 22(4): 363-368. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1525-139X.2009.00581.x>. Go to original source...
    17. Lau WL, Obi Y, Kalantar-Zadeh. Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol 2018; 13(6): 952-961. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.10390917>. Go to original source...
    18. Li C, Liang LV, Wang H et al. Total parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: systematic review and meta-analysis. Ren Fail 2017; 39(1): 678-687. Dostupné z DOI: <http://dx.doi.org/10.1080/0886022X.2017.1363779>. Go to original source...
    19. Wetmore JB. Parathyroidectomy: complex decisions about a complex procedure. Clin J Am Soc Nephrol 2016; 11(7): 1133-1135. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.04950516>. Go to original source...
    20. Holick M. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-281. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra070553>. Go to original source...
    21. Rodriguez M. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288(2): F253-F264. Dostupné z DOI: <http://dx.doi.org/10.1152/ajprenal.00302.2004>. Go to original source...
    22. Martinez Cordellat I. Hyperparathyroidism: Primary or Secondary Disease? Rheumatol Clin 2012; 8(5): 287-291. Dostupné z DOI: <http://dx.doi.org/10.1016/j.reuma.2011.06.001>. Go to original source...
    23. van der Sande FM, Ter Meulen JAK, Kotanko P et al. Dialysate Calcium Levels: Do They Matter? Hemodialysis Int 2019, 47(1-3):230-235. Dostupné z DOI: <http://dx.doi.org/10.1159/000494584>. Go to original source...
    24. Kuragano T, Furuta M, Yahiro M et al. Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patients with low intact-PTH. BMC Nephrology 2013; 14 : 18. Dostupné z DOI: <http://dx.doi.org/10.1186/1471-2369-14-18>. Go to original source...
    25. Šafránek R, Moučka P, Vávrová J et al. Changes of Serum Calcium, Magnesium and Parathyroid Hormone Induced by Hemodialysis With Citrate-Enriched Dialysis Solution. Kidney Blood Press Res 2015; 40(1): 13-21. Dostupné z DOI: <http://dx.doi.org/10.1159/000368478>. Go to original source...
    26. Carsote M, Paduraru DN, Nica AE et al. Parathyroidectomy: is vitamin D a player for a good outcome? J Med Life 2016; 9(4): 348-352.
    27. Redman C, Bodenner D, Brendan N et al. Role of Vitamin D Deficiency in Continued Hyperparathyroidism Following Parathyroidectomy. Head Neck 2009; 31(9): 1164-1167. Dostupné z DOI: <http://dx.doi.org/10.1002/hed.21082>. Go to original source...
    28. Russo D, Tripepi R, Fabio Malberti F et al. Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life". J Clin Med 2019; 8(7): 1066. Dostupné z DOI: <http://dx.doi.org/10.3390/jcm8071066>. Go to original source...
    29. Dusilova Sulkova S, Horacek J, Zivny P et al. Primary hyperparathyroidism associated with hypocalcemia in a patient presenting with kidney disease. Int Nephrol Urol 2010; 42(3): 835-839. Dostupné z DOI: <http://dx.doi.org/10.1007/s11255-010-9743-6>. Go to original source...
    30. Jain N, Reilly RF. Hungry Bone Syndrome. Curr Opin Nephrol Hypertens 2017; 26(4): 250-255. Dostupné z DOI: <http://dx.doi.org/10.1097/MNH.0000000000000327>. Go to original source...
    31. Dusilová Sulková S, Šafránek R, Vávrová J et al. Low-dose Cholecalciferol Supplementation and Dual Vitamin D Therapy in Haemodialysis Patients. Int Urol Nephrol 2015; 47(1): 169-176. Dostupné z DOI: <http://dx.doi.org/10.1007/s11255-014-0842-7>. Go to original source...
    32. Khan A, Bilezikian J. Primary Hyperparathyroidism: Pathophysiology and Impact on Bone. CMAJ 2000; 163(2): 184-187.
    33. Treiber G, Marchal F, Nobecourt E. After Parathyroidectomy: Difficult Short-Term Medical Management in Patients With End-Stage Renal Disease? Hemodial Int 2018; 22(3): 419-420. Dostupné z DOI: <http://dx.doi.org/10.1111/hdi.12670>. Go to original source...
    34. Yalla N, Bobba G, Guo G et al. Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status. J Endocrinol Invest 2019; 42(11): 1353-1360. Dostupné z DOI: <http://dx.doi.org/10.1007/s40618-019-01075-w>. Go to original source...
    35. Bellorin-Font E, Vasquez-Rios G, Martin KJ. Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease. Curr Osteoporosis Int 2019; 17(5): 333-342. Dostupné z DOI: <http://dx.doi.org/10.1007/s11914-019-00533-x.>. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.